LVIS Corporation, headquartered in Palo Alto, California, develops neurotechnology products for neurological healthcare. Its flagship product, NeuroMatch, is an AI-powered, cloud-based SaaS platform that analyses EEG data to identify complex neural network patterns - reducing interpretation time from hours to seconds. The platform has received regulatory clearance from both the U.S. FDA and South Korea's Ministry of Food and Drug Safety (MFDS), and is deployed in major hospitals across the United States and South Korea. LVIS also maintains offices in Seoul and Daegu.
The company's technical foundations draw on more than a decade of research led by founder Jin Hyung Lee, an Associate Professor at Stanford University. LVIS holds exclusive licensing agreements from both Stanford University and UCLA, and participates in the Stanford StartX accelerator, the NVIDIA Inception Program, and the Stanford Byers Center for Biodesign Faculty Fellowship Program. It has received grants from the Stanford Spectrum programme, LivaNova, and the Epilepsy Foundation.
Its technical work spans neurotechnology, EEG analysis, machine learning, cloud infrastructure, computational neuroscience, and medical device regulation. NeuroMatch has been recognised with an AI Excellence Award, and LVIS has been named a finalist for the 2026 Edison Awards.
